MAP1LC3A and diabetes mellitus: Our findings may be translated into clinical practice approach and may lead to further studies to address DM and its vascular complications by selective modulation of ATG5/LC3 expression with new agents such as SGLT2i and newer medications such as DPP4 inhibitors [46–48].